Long-Term Mortality in Patients with Tuberculous Meningitis: A Danish Nationwide Cohort Study by Christensen, Anne-Sophie Halkjær et al.
Long-Term Mortality in Patients with Tuberculous
Meningitis: A Danish Nationwide Cohort Study
Anne-Sophie Halkjær Christensen
1*, Casper Roed
1, Lars Haukali Omland
1, Peter Henrik Andersen
2, Niels
Obel
1,A ˚se Bengaard Andersen
3
1Department of Infectious Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, 2Department of Epidemiology, Statens Serum Institut,
Copenhagen, Denmark, 3Department of Infectious Diseases, Odense University Hospital, Odense, Denmark
Abstract
Background: With high short-term mortality and substantial excess morbidity among survivors, tuberculous meningitis
(TBM) is the most severe manifestation of extra-pulmonary tuberculosis (TB). The objective of this study was to assess the
long-term mortality and causes of death in a TBM patient population compared to the background population.
Methods: A nationwide cohort study was conducted enrolling patients notified with TBM in Denmark from 1972–2008 and
alive one year after TBM diagnosis. Data was extracted from national registries. From the background population we
identified a control cohort of individuals matched on gender and date of birth. Kaplan-Meier survival curves and Cox
regression analysis were used to estimate mortality rate ratios (MRR) and analyse causes of death.
Findings: A total of 55 TBM patients and 550 individuals from the background population were included in the study.
Eighteen patients (32.7%) and 107 population controls (19.5%) died during the observation period. The overall MRR was
1.79 (95%CI: 1.09–2.95) for TBM patients compared to the population control cohort. TBM patients in the age group 31–60
years at time of diagnosis had the highest relative risk of death (MRR 2.68; 95%CI 1.34–5.34). The TBM patients had a higher
risk of death due to infectious disease, but not from other causes of death.
Conclusion: Adult TBM patients have an almost two-fold increased long-term mortality and the excess mortality stems from
infectious disease related causes of death.
Citation: Christensen A-SH, Roed C, Omland LH, Andersen PH, Obel N, et al. (2011) Long-Term Mortality in Patients with Tuberculous Meningitis: A Danish
Nationwide Cohort Study. PLoS ONE 6(11): e27900. doi:10.1371/journal.pone.0027900
Editor: Madhukar Pai, McGill University, Canada
Received September 14, 2011; Accepted October 27, 2011; Published November 22, 2011
Copyright:  2011 Christensen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The study was funded by the Research Foundation at Copenhagen University Hospital, Rigshospitalet. The funders had no role in the study design,
data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: annesophiechristensen@gmail.com
Introduction
Tuberculous meningitis (TBM) is the most devastating mani-
festation of extra-pulmonary tuberculosis (TB) being fatal if left
untreated. Even with standard anti-tuberculous therapy short-term
mortality is high; ranging from 20–69% [1–4]. We have recently
reported a 19% short-term mortality and a high risk of sequelae
(50%) in TBM patients in Denmark over the last decade [4].
The acute, short-term mortality rates in TBM are well
documented, but few studies have analysed long-term mortality.
In this population based cohort study the long-term mortality in
TBM patients was compared to a population control cohort in a
TB and human immunodeficiency virus (HIV) low-endemic
country with equal access to free, public health care.
Materials and Methods
Ethics statement
This study is a registry based cohort study not involving animals
or human subjects – therefore an approval from the Ethical
Committee has not been applicable. The usage of data from the
various registries has been approved by the Danish Data
Protection Agency.
Study design
This study was conducted as a population based nationwide
cohort study. The study populations were all TBM patients
registered in Denmark in the period 1972–2008 and a cohort of
gender and age matched population controls. Outcome was time
to death and to cause-specific death.
Setting
As of January 2008 Denmark had an estimated population of
5.5 million [5]. The reported incidence of tuberculosis (TB), a
mandatory notifiable infectious disease in Denmark, was
6/100,000 in 2009 with 329 new notified cases out of which
65% occurred in immigrants [6]. The incidence of TB in
Denmark declined from the early 1970’s (14/100,000) to the
middle of the 1980’s (4/100,000) where the incidence rose due to
an increase in immigration from TB-endemic countries [7]. The
incidence peaked in 2000 at 10.3/100.000 with 548 new notified
cases [8]. The notified number of TBM cases has consistently been
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estimated HIV prevalence of 0.07% [9]. Throughout the study
period all Danish citizens had free and equal access to public
sector health care and all prescribed anti-tuberculous medications
were available free of charge. The Bacille Calmette Guerin (BCG)
vaccine usage was phased out of the Danish national childhood
vaccination program in the period 1976–1980.
Data sources
The unique 10-digit Central Person Registration (CPR) number
assigned to all Danish citizens at birth or immigration was used to
avoid multiple registrations and to track individuals in the
following registries.
The Danish Tuberculosis Registry (DTBR)
All TB patients are notified to Statens Serum Institute,
Department of Epidemiology, by the treating physician. This
notification is mandatory for all patients initiating anti-tuberculous
treatment.
Data from the DTBR is available from two separate registries; a
historical registry covering all notified cases from 1972–1987 and
the present registry initiated in 1990. Due to a transition period
between the two registries data from the calendar years 1988 and
1989 are missing.
The DTBR contains data on the patient’s CPR number, age,
anatomical localisation of TB, ethnic origin, date of diagnosis,
residence, and, if known, source of TB exposure and/or
information on relapse as well as microbiological data.
In Denmark all TB diagnostics, including microscopy, nucleic
acid amplification (NAA), culture, genotypic identification and
mutation analyses, are centralised at Statens Serum Institute’s
International Reference Laboratory of Mycobacteriology.
The Danish National Patient Registry (DNPR)
DNPR contains information on all patients discharged from
Danish somatic hospitals since 1977 [10]. In 1995 the registry was
expanded to also include psychiatric admissions. Data available
includes the patient’s CPR number, hospital and ward, dates of
admission, and discharge diagnosis codes. These codes follow the
International Classification of Diseases, Eighth Revision (ICD-8), until
the end of 1993 and the Tenth Revision (ICD-10) thereafter. The
physician can code one primary and up to 19 secondary discharge
diagnoses. From this registry, date of first admission with TBM
was extracted.
Civil Registration System (CRS)
The CRS was established in 1968 and contains information on
vital status, residency, immigration and/or emigration status on all
Danish residents [11]. The following data was extracted: date of
birth, gender, date of immigration or emigration, location of
residence and date of death.
Danish Registry of Causes of Death (DRCD)
DRCD contains data from all Danish death certificates since
1943 [12] – the registry is currently updated to 31 December
2009. Causes of death are coded according to the ICD-8 until the
end of 1993 and according to the ICD-10 thereafter. The
physician in charge can code one immediate cause of death
followed by secondary and/or tertiary causes of death and finally
one underlying cause of death. The underlying cause of death was
in our study considered to be the specific cause of death and these
codes were extracted for all TBM patients and population controls
that died and categorised as listed in Appendix S1.
Study population
Tuberculous meningitis patients. We included all patients
who: 1) were notified to the DTBR from 1 January 1972 until 31
December 2008 and 2) were registered in the DNPR with a
diagnosis of TBM or tuberculoma (ICD-8 codes 013.00–014.00
and the following ICD-10 codes: A 17.0–17.1, A 17.8A, A 17.8D)
and 3) were $16 years of age at TBM diagnosis, and 4) were
registered in the CRS. The date of TBM diagnosis was defined as
the date of first admission for TBM according to DNPR, and the
index date as one year after TBM diagnosis. Patients were
excluded from the study population when they died, emigrated or
were lost to follow-up within the first year after TBM diagnosis.
Population control cohort. From the CRS we identified ten
random population controls for each TBM patient included in the
study population. Each population control was matched on gender
and date of birth (month and year) with the corresponding TBM
patient; also, the population controls had to be alive and living in
Denmark on the index date (i.e. one year after diagnosis) of the
respective TBM patient. The index date for the population
controls was hence the same as for the TBM patient to whom they
were matched.
Comorbidity
A modified Charlson Comorbidity Index (CCI) score was used
as a measurement of comorbidity. This score is derived from
DNPR diagnoses prior to the first TBM diagnosis. A score of 1, 2,
3 or 6, is assigned to a range of co-morbid conditions, such as
ischemic heart disease, cancer, liver disease or acquired immune
deficiency syndrome (AIDS). This score is correlated to the
mortality associated with the condition [13]. The sum of individual
scores serves as a comorbidity parameter. Three levels of
comorbidity were defined: none (CCI score=0), low (CCI
score=1–2) or high (CCI score.3).
Outcome
Primary study outcome was time from index date to death and
cause-specific death.
Statistical analysis
We used chi-square or, where appropriate, Fischer’s exact test
to compare categorical data for cases and controls. Continuous
data was compared using the Kruskal-Wallis test. Time was
calculated from index date to the date of death, emigration, loss to
follow-up or 31 December 2009, whichever came first. Kaplan-
Meier analyses were used to construct survival curves. Cox
proportional hazard regression analyses were used to calculate
mortality rate ratios (MRR). Schoenfeld plots confirmed that the
proportional hazard assumptions were fulfilled. MRR were
adjusted for Charlson Comorbidity Index score (categorical
ordinal variable) as calculated up to two years prior to TBM
diagnosis to minimise risk of confounding. SPSS version 15.0 for
Windows and R version 2.13 were used for data analysis. The
study was approved by the Danish Data Protection Agency.
Results
Characteristics of the study population
In the period 1972–2008 a total of 127 patients were identified
with TBM in DNPR and DTBR. Within the first year of
diagnosis, 45 patients died (32%), two emigrated and 25 were less
than 16 years of age at diagnosis leaving 55 in the study
population.
Baseline characteristics of the 55 patients and their 550
population controls are shown in Table 1. A total of 42 cases
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microscopy, NAA or culture). There was an equal sex distribution
among the TBM patients and the median age at time of TBM
diagnosis was 39.5 years (IQR: 29.0–56.4 years). More than half
the patients were between 31 and 60 years of age at time of
diagnosis. Thirty percent of the immigrant patients were between
16–30 years at time of diagnosis whereas only 20% of the Danish
patients were in this age category. Likewise, we found a higher
percentage of Danish patients (28%) versus immigrants (10%) in
the age category .60 years at time of diagnosis.
There were fewer patients diagnosed in the 1970’s compared to
the three other decades. The age at time of diagnosis was,
however, evenly distributed in the four decades. The level of
comorbidity two years prior to TBM diagnosis did not differ
between the TBM and the control population; a total of 5,4% of
the TBM patients had either a low or high Modified Charlson
Comorbidity Index compared to 4,7% in the population control
cohort. Four of the TBM patients (7.3%) were HIV positive
compared to none in the control group.
The number of TBM patients with a known TB diagnosis prior
to time of TBM diagnosis was 15 (27.3%) – compared with only 1
(0.18%) case in the population control cohort. Nine (60%) of these
patients with a history of TB were immigrants and ten (66.7%) had
been diagnosed with TB within one year prior to TBM. The
specific previous TB diagnoses were pulmonary TB (7 cases,
46.7%) and extra-pulmonary TB (8 cases, 53.3%).
Overall mortality
A total of 18 (32.7%) TBM patients and 107 (19.5%) population
controls died during the observation period (Table 2). The median
age at time of death was 65.1 years (IQR: 54.1–78.9) among the
TBM patients and 74.1 years (IQR: 64.0–83.3) in the population
control cohort. Figure 1 depicts Kaplan-Meier survival curves for
TBM patients and the population controls. The TBM patients
were at increased risk of death throughout the entire observation
period compared to the population controls. We found an overall
MRR of 1.79 (95% CI: 1.09–2.95) for the TBM patients and
adjustment for comorbidity did not change the estimate. It
appeared, when stratified on individual risk factors, that males
were at higher risk of death than women (adjusted MRR 1.99;
95% CI: 0.98–4.07). When stratified on age at time of TBM
diagnosis, we found that patients in the 31–60 age group had the
highest relative risk of death compared to other age groups
(adjusted MRR 2.68, 95% CI: 1.35–5.35). There was a trend
towards an increased relative risk of death in immigrant patients
(adjusted MRR 2.39; 95% CI: 0.90–6.39).
Table 1. Characteristics of tuberculous meningitis (TBM) patients and population controls, Denmark 1972–2008.
TBM patients Controls P-value
Total included, no 55 550
Males, no (%) 27 (49.1) 270 (49.1)
Ethnic Danes, no (%) 25 (45.5) 492 (89.5) ,0,001
Observation time (total), yrs 668.5 7242.3
Observation time, median (IQR), yrs 8.8 (4.39–19.64) 10.46 (5.68–22.18)
Lost to follow-up during study period, no (%) 1 (1.8) 0
Emigrated during study period, no (%) 2 (3.6) 20 (3.6)
Age at diagnosis, median (IQR), yrs 39.5 (29.0–56.4) 39.5 (29.0–56.4)
Age at diagnosis by age intervals, no (%)
16–30 yrs 14 (25.5)
31–60 yrs 31 (56.4)
.61 yrs 10 (18.2)
Patients diagnosed by decade, no (%)
1972–1980 7 (12.7)
1981–1990 15 (27.3)
1991–2000 17 (30.9)
2001–2010 16 (29.1)
Age at diagnosis by decade, median (IQR), yrs
1970–1980 42.8 (28.5–67.1)
1981–1990 36.9 (25.1–54.8)
1991–2000 43.7 (32.9–56.4)
2001–2011 39.6 (30.9–53.7)
Modified Charlson Comorbidity Index 2 years prior to TBM diagnosis, no (%)
None (score=0) 52 (94.5) 524 (95.3)
Low (score=1–2) 2 (3.6) 25 (4.5)
High (score$3) 1 (1.8) 1 (0.2)
Tuberculosis diagnosis prior to TBM 15 (27.3) 1 (0.2) ,0,001
HIV diagnosis prior to TBM diagnosis 4 (7.3) 0
doi:10.1371/journal.pone.0027900.t001
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As shown in Table 3, TBM patients were at higher risk of
infectious disease related death than the population controls with
an adjusted MRR of 42.8 (95% CI: 9.09–201.74). The specific
infectious disease causes of death were TB-related in four out of
eight TBM patients with infectious disease related cause of death,
whereas none of the population controls had a TB-related
underlying cause of death. TBM patients were at similar risk of
death due to non-infectious disease causes as their population
controls.
Table 2. Mortality rate ratios (MRR) for tuberculous meningitis patients compared to population controls.
Unadjusted
MRR (95% CI)
Adjusted
MRR* (95% CI)
Number of patients
who died (%)
Number in the control
population who died (%)
All 1.79 (1.09–2.95) 1.76 (1.07–2.91) 18 (32.7) 107 (19.5)
Stratified on risk factors
Sex
Female gender 1.58 (0.78–3.20) 1.56 (0.77–3.16) 9 (32.1) 57 (20.4)
Male gender 2.05 (1.01–4.16) 1.99 (0.98–4.07) 9 (33.3) 50 (18.5)
Ethnicity
Native Danes 1.61 (0.90–2.89) 1.60 (0.89–2.87) 13 (52) 86 (34.4)
Immigrants 2.46 (0.93–6.53) 2.39 (0.90–6.39) 5 (16.7) 21 (7)
Age at diagnosis
16–30 yrs 2.02 (0.24–17.29) 2.01 (0.23–17.19) 1 (7.1) 5 (3.6)
31–60 yrs 2.68 (1.34–5.34) 2.68 (1.35–5.35) 10 (32.3) 43 (13.9)
.61 yrs 1.23 (0.56–2.74) 1.11 (0.47–2.61) 7 (70) 59 (59)
*Adjusted for Charlson Modified Comorbidity Index two years prior to TBM diagnosis.
doi:10.1371/journal.pone.0027900.t002
Figure 1. Kaplan-Meier survival curve of patients with tuberculous meningitis (dashed line) and population controls (solid line),
Denmark, 1972–2008.
doi:10.1371/journal.pone.0027900.g001
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In this nationwide, population based cohort study with up to 30
years of follow-up, we observed a nearly two-fold increased long-
term risk of death in TBM patients compared to the background
population. The increased effect of TBM on mortality was mainly
seen in males; patients 31–60 years of age at time of diagnosis and
immigrants. Also, we observed that TBM patients primarily die of
infectious disease associated causes, in particular TB-related causes
of death. Our study results are of value both to the treating
physician and to the patients and their families, who want to know
the long-term prognosis after having survived the first year after a
TBM diagnosis.
To our knowledge this is the first study to address the issue of
long-term mortality in TBM patients in a population-based cohort
study design. Previous studies include the initial clinical trials of
Streptomycin for the treatment of TBM from the 1940’s, where
64% of the patients died within an observation period ranging
from four months to just under one year [14]. In a recent case-
control study from the United States [15], a hazard ratio for death
of 3.72 (95% CI 1.82–7.60) in 135 patients with TBM compared
to 75 controls with non-proven TBM with an observation period
of maximum nine years was reported. This estimate is higher than
our estimate due to the observation period including also the first
year after TBM diagnosis. The most frequently reported definitive
cause of death was, consistent with our findings, TBM itself. Our
study addresses long-term mortality in TBM patients in a more
explicit way by comparing mortality in two study groups – one
with clearly defined TBM and the other without. Also, our
populations are matched on gender and age minimising risk of
confounding, and our observation time is significantly longer.
TBM is associated with a high level of morbidity [2,4,16,17].
The most commonly reported neurological sequelae among TBM
patients are epilepsy, cognitive impairment, cranial nerve palsy
and motor deficits [18–20]. Despite these well-documented
neurological sequelae, the risk of death from neurology related
causes of death was not increased in our TBM patient population.
On the contrary, the analysis of cause-specific death revealed that
even long-term mortality is registered as TBM being the
underlying cause of death.
In a recent large cohort study analysing long-term mortality in
Danish patients with meningococcal disease (of which the majority
had meningitis) only a slightly increased overall MRR of 1.27
(95% CI 1.12–1.45) was found. Interestingly, these patients were
at increased risk of death due to nervous system diseases (MRR
3.57; 95% CI: 1.82–7.00) but not at increased risk of death due to
infectious diseases [21]. The excess mortality and increased risk of
death due to neurological causes were ascribed long-term sequelae
to the disease. Similarly, in a study reporting long-term mortality
in patients diagnosed with pneumococcal meningitis in Denmark
[22], a high level of morbidity was apparent as patients were at
increased risk of death due to nervous system disease but not to
infectious diseases in general.
The high MRR reported in our study is noteworthy given that
Denmark is a setting of both low TB and HIV prevalence and a
country with a well developed national health care system where
all patients are treated free of charge. The in-patient mortality
rates are generally similar for HIV and non-HIV positive TBM
patients [3,23]. However, when looking at 9-month survival in
TBM patients, a Vietnamese study found a significantly increased
mortality (MRR 2.91; 95%CI: 2.14–3.96) in HIV positive patients
[24].
Even though the main objective of this study was to address the
long-term mortality, it is important to underline the observed 32%
mortality among TBM patients within the first year of diagnosis.
This is higher than the 19% short-term mortality recently reported
in a retrospective study regarding TBM patients diagnosed in
Denmark from 2002–2008 [4]. This may reflect a trend in
declining short term mortality, perhaps due to some progress in
diagnostics, such as NAA and magnetic resonance imaging (MRI).
Also, dexamethasone has become a part of routine anti-
tuberculous meningitis treatment after it proved to significantly
reduce short-term mortality rates [25].
A large proportion of the patients in our study had been
diagnosed with TB in the year leading to TBM diagnosis. It is
unlikely that the subsequent development of TBM could be
attributed drug-resistant TB, since drug-resistant TB constitutes a
minor problem in Denmark. A recent study showed that 6.1% of
all culture-confirmed TB cases in Denmark in the period 2002–
2007 had monoresistance or polyresistance to isoniazid [26].
Multi-drug resistant (MDR) TB cases are very rare with a reported
incidence of 0.5% from 1992–2007 [27]. The monitoring of drug-
resistant TB in Denmark is intensive, as all new cases undergo
drug-susceptibility testing at Statens Serum Institute. The general
rate of recurrent TB is low in Denmark, as shown in a recent study
with a 13.5 year follow-up, where relapse accounted for only 1.3%
of the recurrent cases [28]. It is possible that the TBM patients in
this cohort had compliance problems leading to an increased risk
of relapse; however, this question exceeds the aim of this study.
The apparent effect modification with regards to gender and MRR
may be caused by males with TB being more socially marginalized
than females with TB. The effect modification with regards to age
and MRR is probably a result of an increased mortality in the
population control cohort of individuals above the age of 60 years,
which leads to a decrease in relative risk of death [29].
Table 3. Cause specific mortality rate ratios in TBM patients compared with population controls.
Cause of death
Deaths in TBM
patients, n
Deaths in population
controls, n
Unadjusted
MRR* (95% CI)
Adjusted
MRR** (95% CI)
Infectious disease related death 8 2 42.70 (9.07–201.11) 42.83 (9.09–201.74)
Tuberculosis of the central nervous system 4 0 - -
HIV 2 1 - -
Other infectious diseases 2 1 - -
Non-infectious disease related death 10 105 1.01 (0.53–1.94) 0.99 (0.52–1.90)
*Unadjusted MRR not calculated for all causes of death due to few events.
**Adjusted for modified Charlson Comorbidity Index score two years prior to TBM diagnosis.
doi:10.1371/journal.pone.0027900.t003
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disease in the Danish population, it was only possible to include a
small population of 55 TBM patients reducing the statistical power
of our results. We were not able to match our study population on
ethnicity; in our stratified MRR calculations, the MRR shows a
greater impact of TBM in immigrant patients. However, since the
impact of TBM on mortality was greater in younger patients, the
increased effect of TBM in immigrants could be explained by the
demographic constellation of this group having a greater
proportion of younger patients rather than by an effect of
ethnicity.
The patients included in this study have all been notified with a
TB diagnosis to the DTBR over a more than 30 year period. By
pairing data with data on TBM discharge diagnoses from the
DNPR we have minimized the risk of misclassifying disease status
in the study population. The diagnosis in 76% of the TBM
patients was microbiologically verified. There is no risk of loss-to-
follow-up bias due to only one study participant falling in this
category. The usual risk of confounding attributed to gender and
age is not present in our study because population controls were
matched on exactly these two factors. The unique and validated
Danish registries along with a follow-up time of up to 30 years add
further strength to the study.
Conclusion
In this population based cohort study adult patients diagnosed
with TBM were shown to have a life-long increased risk of death
compared to the background population. Despite one third of
TBM patients dying during the first year after diagnosis, the
prognosis remains bleak thereafter – even in a high-income, low
TB- and HIV-endemic setting.
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